Early Recognition and Intervention in Cancer Cachexia - Webinar Part 1

In a recent webinar, Professors Aminah Jatoi, Jeffrey Crawford, and Rony Dev delved into the multifaceted nature of cancer cachexia, examining its definition, underlying pathophysiology, and profound impact on patients' quality of life. The session underscored the critical importance of early diagnosis and timely intervention, highlighting a multidisciplinary approach that includes nutritional support, physical activity, and pharmacologic therapies.

Target Audience

Healthcare Professionals

Learning Objectives

  • Gain a comprehensive understanding of the multifactorial nature of cancer cachexia, including its prevalence, clinical impact, and disease burden.​
  • ​Understand the clinical symptoms, diagnostic criteria, and staging of cancer cachexia, and emphasize the importance of early recognition​ 
  • Develop skills to implement a multi-modal approach to managing cancer cachexia.​ 
  • Create effective communication strategies to inform patients and their care providers about cancer cachexia.​

This activity is supported by an educational grant from Pfizer.

Course summary

Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
Course opens: 
06/09/2025
Course expires: 
06/04/2028
Cost:
$0.00
Aminah Jatoi, M.D

Aminah Jatoi, M.D

Betty J. Foust, MD and Parents' Professor of Oncology, Mayo Clinic, Rochester, Minnesota

Aminah Jatoi, M.D discloses the following: DSM/Advisory Board Fees: Pfizer, honorarium to institution

Dr. Rony Dev

Dr. Rony Dev

Associate Professor, Department of Palliative Care and Rehabilitation Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.

Dr. Rony Dev discloses the following: Other Relationships: royalties, UpToDate, and Wolters Kluwer Publishing

Professor Jeffrey Crawford

Professor Jeffrey Crawford

George Barth Geller Professor Emeritus for Research in Cancer, Department of Medicine, Duke University Medical Center

Professor Jeffrey Crawford discloses the following: Advisory Board Member: Actimed Therapeutics, Pfizer, Tensegrity Pharma
Data Safety Monitoring Board: Pharmacosmos
Site PI/Institutional Funding: AstraZeneca, Pfizer

Accreditation Statement 

John Wiley and Sons, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

John Wiley and Sons, Inc. designates this activity for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™

Price

Cost:
$0.00
Please login or register to take this course.